Vaccines, Pneumococcal Conjugate Vaccine Clinical Trial
Official title:
A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Brazil
The purpose of this study will be to analyze 13-valent pneumococcal vaccine given to healthy infants in Brazil for safety and tolerability, and to determine the immune response to the vaccines.
n/a
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00574795 -
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants
|
Phase 3 | |
| Completed |
NCT00269672 -
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
|
Phase 2 | |
| Completed |
NCT00580684 -
Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children
|
Phase 4 | |
| Completed |
NCT00500357 -
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
|
Phase 3 | |
| Completed |
NCT00581620 -
Study Evaluating Prevenar Immunogenicity in High Risk Children
|
Phase 4 | |
| Completed |
NCT00475033 -
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
|
Phase 3 | |
| Completed |
NCT00980655 -
Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
|
Phase 3 | |
| Completed |
NCT00683410 -
Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)
|
N/A |